Skip to content
PageTrader
  • Home
  • Products
    • Williams Edge Futures
    • Williams Edge S&P
    • Williams Edge Plus
    • Squares Principal
    • Reflected Wave
  • Customer Login
  • Past Performance
  • Trial
  • Testimonials
  • Calendar
  • Contact Us
  • Cart / $0.00
    0

01/29/2015 – Salix Pharmaceuticals Ltd.

  • January 29, 2015
  • Salix Pharmaceuticals Ltd.

Issued: 01/29/2015

Salix Pharmaceuticals Ltd, SLXP:

1. Our previous (Tues. January 27) report on Salix Pharmaceuticals indicated new long entry upon any hourly or especially a daily close above $127.50 for further advance and test/attempt at 134.50/$136.50 (or higher) into next week (week of Feb. 2 +/-1 week).

2. In spite of the recent (forecast) broad market decline Salix Pharmaceuticals advanced powerfully today (Thurs., Jan. 29) and completed the $136.50 upside profit target (today’s session high, $137.61, so far).

3. Partial long position exits were taken at/near the $134.50 initial target, further exits were taken at/near $136.50. Will message any remaining long position exits in a subsequent update.

4. Our protective sell stop has been placed at $131.50. This stop will be moved higher as the market continues to confirm.

David Williams

Issued: 02/04/2015

Salix Pharmaceuticals Ltd, SLXP:

1. Our previous (Tues. January 27) report on Salix Pharmaceuticals indicated new long entry upon any hourly or especially a daily close above $127.50 for further advance and test/attempt at 134.50/$136.50 (or higher) into next week (week of Feb. 2 +/-1 week).

2. On Thurs., Jan. 29 Salix Pharmaceuticals completed the $136.50 upside profit target.

3. Final long position exit should now be taken at current prices (current price, $139.78). This completes the trade. Will message any further entry or indication in Salix Pharmaceuticals.

David Williams

Issued: 01/26/2015

Salix pharmaceuticals Ltd, SLXP:

1. During recent Williams edge live stock meetings it was noted that Salix pharmaceuticals was in position for further advance and test/attempt at $135/$37 into Friday (Jan. 23/Mon. Jan. 26).

2. While the price portion of the forecast was correct, the week of Jan. 26 (+1 week) is the correct timeframe that the price targets are expected. Will message any new entry based upon this as the market confirms during this week.

David Williams

Issued: 01/27/2015

Salix Pharmaceuticals Ltd, SLXP:

1. Any hourly or especially a daily close above $127.50 will place Salix Pharmaceuticals Ltd in a ‘Buy’ position for further advance and test/attempt at 134.50/$136.50 (or higher) into next week (week of Feb. 2 +/-1 week).

2. Initial long position exit should be taken at/near $131 and further exit taken at/near $134. Any remaining long position should be held for higher prices to be messaged in a subsequent update.

3. A protective sell stop will be messaged upon confirmation as noted above.

David Williams

CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

Members of

PageTrader, Ltd. is a BBB Accredited Business Consultant in Las Vegas, NV

Links

  • Trading Disclaimer
  • Privacy Policy
  • About Us
  • Cancellation and Refund Policy
  • Contact Us

 

  • Home
  • Market Forecasting Products
  • Customer Login
  • Webinar Calendar
CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.
CLICK HERE TO READ OUR FULL TRADING DISCLAIMER
Copyright ©2000-2021 PageTrader, Ltd. All Rights Reserved.